Trials / Completed
CompletedNCT04729309
Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers
Open-Label Study to Investigate the Mass Balance and Absolute Bioavailability of a Single Oral Dose of [14C]-Labeled RO7049389 or RO7049389 and an Intravenous Micro-Dose of [13C]-Labeled RO7049389 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to characterize the mass balance, absolute bioavailability, route and rates of elimination of RO7049839.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [12C] RO7049389 | Participants will receive oral \[12C\] RO7049389. |
| DRUG | [13C] RO7049389 | Participants will receive IV \[13C\] RO7049389. |
| DRUG | [14C] RO7049389 | Participants will receive an oral suspension of \[14C\] RO7049389. |
Timeline
- Start date
- 2021-03-31
- Primary completion
- 2021-06-14
- Completion
- 2021-06-14
- First posted
- 2021-01-28
- Last updated
- 2024-07-15
- Results posted
- 2024-07-15
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04729309. Inclusion in this directory is not an endorsement.